Jakafi Xr (ruxolitinib phosphate)
New formulation or manufacturer
- Region
- 🇺🇸 US
- Active substance
- ruxolitinib phosphate
- Company
- Incyte Corp
- Status
- Approved
- FDA approval
- Fri 01 May 2026
- Designations
- New formulation or manufacturer
- Application
- NDA217180
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Fri 01 May 2026🇺🇸 FDA approval
FDA approves Jakafi Xr (ruxolitinib phosphate): new formulation or manufacturer
Incyte Corp; NDA217180; New formulation or manufacturer; tablet, extended release · source
Follow Jakafi Xr
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.